BB:TUB Financičre de Tubize SA

Financičre de Tubize S.A., through its interest in UCB SA/NV, operates as a biopharmaceutical company worldwide. It discovers and develops medicines and solutions in the therapeutic areas of neurology and immunology diseases. The company's principal products include Cimzia for treating ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, psoriatic arthritis, and rheumatoid arthritis; Briviact to treat epilepsy; Vimpat for the treatment of epilepsy partial-onset seizures; Neupro for treating Parkinson's disease and restless legs syndrome; and Keppra for treating partial-onset seizures, primary generalized tonic-clonic seizures, and myoclonic seizures for patients diagnosed with epilepsy. It also offers Zyrtec and Xyzal for allergy; Nootropil for the treatment of psycho-organic syndromes or cognitive decline and cortical myoclonus; and Xyrem for use in treating narcolepsy with cataplexy in adult patients. The company's products in pipeline include UCB0942 for drug resistant epilepsy; UCB3491 for epilepsy; UCB1332/NPT200-11 for Parkinson's disease; UCB7858 for auto-inflammatory diseases; UCB6673 and UCB7665 to treat immunological diseases; UCB4144/VR942 to treat asthma; seletalisib for treating Sjörgen's syndrome; bimekizumab and Cimzia combo for rheumatoid arthritis; dapirolizumab pegol for systemic lupus erythematosus; bimekizumab to treat various arthritis and dermatology indications; and romosozumab for post-menopausal osteoporosis. Financičre de Tubize S.A. is based in Brussels, Belgium.

85.60 EUR
As of 01/14/2022

Security Information
Category1:  Global Equity
Category2:  Common stocks
Category3:  Developed markets ex-US
GICS sector:  Financials
Industry:  Biotechnology
Index country:  Belgium
Country of incorporation:  Belgium
IPO date:  01/03/2000
Stock exchange:    Nyse Euronext - Euronext
Exchange country:   Belgium
Market cap:   3,807,196,928 EUR
Current dividend yield:   0.80%
Sedol:      B0BN7W8

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy